中大職務
- 醫學院助理院長 (學習體驗)
- 郭氏集團腸胃及肝臟科教授
- 內科及藥物治療學系腸胃及肝臟科主任 (學術事務)
- 消化疾病研究所教授
- 消化疾病研究全國重點實驗室(香港中文大學)教授
專業範疇
- 腸胃及肝臟科專科
- 肝炎
- 肝癌
- 肝纖維化
- 消化性潰瘍
教育及資歷
MBChB (CUHK), MD (CUHK), FRCP (Lond, Edin), FHKCP, FHKAM (Medicine)
專注研究
乙型及丙型肝炎
肝癌
無創性肝纖維化診斷
原發性消化性潰瘍
醫學大數據研究
更多資訊
獎項及榮譽
- 美國肝病研究學會會士, 2026
- 科睿唯安 (Clarivate Analytics) 全球最廣獲徵引研究人員《臨床醫學》, 2025
- 科睿唯安 (Clarivate Analytics) 全球最廣獲徵引研究人員《跨領域》, 2024
- 醫務衞生局COVID-19卓越研究隊伍獎項, 2024
- 科睿唯安 (Clarivate Analytics) 全球最廣獲徵引研究人員《跨領域》, 2023
- 廣東省科學技術獎一等獎, 2024
- 香港內科醫學院研究員奬項
- Asian-Pacific Association for the Study of the Liver (APASL), Kyoto, 2024
- 《肝病學雜誌》最佳評審員奬, 2022
- 香港內科醫學院余宇康講座席, 2021
- 世界肝炎峰會Presidential Awards (公共衞生), 2021
- 亞太肝病學會Presidential Plenary Award, 2019
- 《Clinical and Molecular Hepatology》最佳評論論文獎, 2018
- 廣東省科學技術獎一等獎, 2018
- JGH基金會JGHF新晉領袖講座獎, 2017
- 香港內科醫學院達安輝爵士講座席, 2016
- 香港內科醫學院傑出研究論文獎, 2010, 2013, 2014, 2015
- 香港十大傑出青年, 2014
- 第22屆亞太肝臟研究協會年會 Travel Grant Award, 2012
- 亞太肝臟研究協會「青年學者獎」, 2009
- 香港醫學專科學院最佳學員原創研究獎銅獎, 2008
專業服務
- 醫院管理局臨床統籌委員會 (COC) 內科/腸胃科召集人
- 《Hepatology》副編輯
- 亞太肝臟研究協會 Clinical Practice Guidelines for Chronic Hepatitis B 2026 委員會成員
中大教學職務
- 消化疾病理學碩士課程總監
部分論文 (只有英文版本)
- Wong GL, Yuen MF, Lin B, et al. Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial. Nat Med 2026;32:151-159.
- Wong GL, Gane E, Pan CQ, et al. Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment. Aliment Pharmacol Ther 2026;63:132-144.
- Wong GL, Lemoine M. The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines. J Hepatol 2025;82:918-925.
- Wong GL. Updated Guidelines for the Prevention and Management of Chronic Hepatitis B-World Health Organization 2024 Compared With China 2022 HBV Guidelines. J Viral Hepat 2024;31 Suppl 2:13-22.
- Wong GL, Yip TC, Lai MS, et al. Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir. JAMA Netw Open 2022;5:e2245086.
- Wong GL, Hui VW, Yip TC, et al. Minimal risk of drug-induced liver injury with molnupiravir and ritonavir-boosted nirmatrelvir. Gastroenterology 2023;164:151-153.
- Wong GL, Ong JP, Kaewdech A, Su TH. Halfway through HBV elimination - are we not waiting? Int J Infect Dis. 2023;134:299-300.
- Wong GL, Gane E, Lok ASF. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? J Hepatol 2022;76:1249-1262.
- Wong GL, Hui VW, Tan Q, et al. Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. JHEP Rep 2022;4:100441. doi: 10.1016/j.jhepr.2022.100441. eCollection 2022 Mar.
- Wong GL, Wong VW, Hui VW, et al. Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. Am J Gastroenterol 2021;116:1274-1283.